MLICM
THRD

Metropolitan Life Insurance Company (MetLife)’s Third Harmonic Bio THRD Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,255
Closed -$11.8K – 1916
2024
Q1 		$11.8K Hold
1,255
– – ﹤0.01% 2073
2023
Q4 		$13.8K Hold
1,255
– – ﹤0.01% 2066
2023
Q3 		$8.02K Buy
+1,255
New +$7.67K ﹤0.01% 2313

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s THRD Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Third Harmonic Bio (THRD) in Q2 2024, closing a stake of 1,255 shares — an estimated $11.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in THRD in Q3 2023 and held it in 3 quarters. The position peaked at $13.8K in Q4 2023. 77 funds tracked by Wall St. Rank hold THRD as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Third Harmonic Bio position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,255 Third Harmonic Bio shares in Q2 2024, an estimated $11.8K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Third Harmonic Bio in Q3 2023 and held it in 3 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Third Harmonic Bio position peaked at $13.8K in Q4 2023.
  • 77 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.